180 related articles for article (PubMed ID: 37885171)
1. Look What the Cat Dragged in! Recurrent Clostridioides difficile from a Household Cat.
Garza MA; Thomas B; Saleh A; Nabbout L; Quigley EMM; Mathur N
Am J Case Rep; 2023 Oct; 24():e940923. PubMed ID: 37885171
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
[TBL] [Abstract][Full Text] [Related]
4.
Tsai CS; Hung YP; Lee JC; Syue LS; Hsueh PR; Ko WC
Expert Rev Anti Infect Ther; 2021 Dec; 19(12):1543-1552. PubMed ID: 34383624
[TBL] [Abstract][Full Text] [Related]
5. Clostridioides difficile associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges.
Shah KJ; Cherabuddi K; Pressly KB; Wright KL; Shukla A
BMC Nephrol; 2020 Mar; 21(1):76. PubMed ID: 32131755
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
Johnson SW; Brown SV; Priest DH
Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
[TBL] [Abstract][Full Text] [Related]
7. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
8. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
9. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation.
Tubau-Juni N; Bassaganya-Riera J; Leber AJ; Alva SS; Hontecillas R
Inflamm Bowel Dis; 2024 Jan; 30(1):103-113. PubMed ID: 37436905
[TBL] [Abstract][Full Text] [Related]
10. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
11. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
Finn E; Andersson FL; Madin-Warburton M
BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
[TBL] [Abstract][Full Text] [Related]
12. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea.
Abad CLR; Safdar N
Gastroenterol Clin North Am; 2021 Jun; 50(2):323-340. PubMed ID: 34024444
[TBL] [Abstract][Full Text] [Related]
13. Clostridioides difficile infection evaluation and management in the emergency department.
Carius BM; Liang SY; Koyfman A; Long B
Am J Emerg Med; 2020 Oct; 38(10):2203-2208. PubMed ID: 33071079
[TBL] [Abstract][Full Text] [Related]
14. Frontiers in antibiotic alternatives for
Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
[No Abstract] [Full Text] [Related]
15. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.
Dalal RS; Allegretti JR
Curr Opin Gastroenterol; 2021 Jul; 37(4):336-343. PubMed ID: 33654015
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
[TBL] [Abstract][Full Text] [Related]
17. An insight into
Thabit AK; Aljedaani HJ; Alghamdi RH; Badahdah RM; Lashkar MO; Alnajjar A
Expert Rev Gastroenterol Hepatol; 2023; 17(8):805-810. PubMed ID: 37480286
[TBL] [Abstract][Full Text] [Related]
18. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
19. Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature.
Adams DJ; Barone JB; Nylund CM
J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S22-S26. PubMed ID: 34791398
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of recurrent Clostridium difficile infection in out-patients.
Shivashankar R; Khanna S; Kammer PP; Scott Harmsen W; Zinsmeister AR; Baddour LM; Pardi DS
Aliment Pharmacol Ther; 2014 Sep; 40(5):518-22. PubMed ID: 25039269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
